NASDAQ:PALI Palisade Bio Q1 2026 Earnings Report $2.00 -0.03 (-1.24%) As of 09:42 AM Eastern This is a fair market value price provided by Massive. Learn more. ProfileEarnings HistoryForecast Palisade Bio EPS ResultsActual EPS-$0.05Consensus EPS -$0.04Beat/MissMissed by -$0.01One Year Ago EPSN/APalisade Bio Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/APalisade Bio Announcement DetailsQuarterQ1 2026Date5/12/2026TimeAfter Market ClosesConference Call DateTuesday, May 12, 2026Conference Call Time7:00AM ETUpcoming EarningsPalisade Bio's Q3 2026 earnings is estimated for Monday, November 9, 2026, based on past reporting schedules, with a conference call scheduled on Tuesday, November 10, 2026 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)SEC FilingEarnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Palisade Bio Earnings HeadlinesPalisade Bio to Participate in Upcoming Investor ConferencesSeptember 3, 2026 | globenewswire.comPalisade Bio, Inc.: Palisade Bio Reports Second Quarter 2026 Financial Results and Highlights Continued Advancement of PALI-2108 Into Phase 2 DevelopmentAugust 11, 2026 | finanznachrichten.deThe national debt just passed $39 trillionThe U.S. national debt just topped $39 trillion, up nearly $3 trillion in a single year and on pace to hit $40 trillion by fall. Servicing that debt now costs more than the entire defense budget, while inflation above 3.5% keeps eroding cash savings. Central banks are responding by buying gold at the fastest pace in decades. The U.S. Gold Bureau's complimentary guide covers IRA-eligible gold and silver options, secure storage, and a fast BuyBack Guarantee.September 16 at 1:00 AM | US Gold Bureau (Ad)Analysts’ Top Healthcare Picks: Palisade Bio (PALI), Sarepta Therapeutics (SRPT)August 11, 2026 | theglobeandmail.comPalisade Bio Reports Second Quarter 2026 Financial Results and Highlights Continued Advancement of PALI-2108 Into Phase 2 DevelopmentAugust 10, 2026 | finance.yahoo.comPalisade Bio Reports Q2 2026 Results, Advances PALI-2108 Into Phase 2 Development for Ulcerative Colitis and Crohn’s DiseaseAugust 10, 2026 | quiverquant.comQSee More Palisade Bio Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Palisade Bio? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Palisade Bio and other key companies, straight to your email. Email Address About Palisade BioPalisade Bio (NASDAQ:PALI) is a clinical-stage biopharmaceutical company focused on developing therapies for gastrointestinal diseases and conditions associated with intestinal inflammation, impaired gut-barrier function and complications following surgery. The company’s lead product candidate is LB1148, an orally administered, non-absorbed pan-serine protease inhibitor. Palisade Bio is evaluating LB1148 for its potential to limit the harmful effects of digestive enzymes, reduce inflammation and support intestinal healing during the postoperative period. The program has been studied in clinical trials involving patients undergoing abdominal surgery, including research related to postoperative ileus and other complications that can delay recovery. Palisade Bio’s development activities are centered on advancing LB1148 through clinical testing and evaluating additional applications for the compound in gastrointestinal and surgical-care settings. As a development-stage biotechnology company, its products remain investigational and are not broadly marketed as approved therapies. The company is headquartered in the United States and focuses its clinical development efforts on markets governed by U.S. and international regulatory authorities.View Palisade Bio ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Marex Stock Doubles on Record Profits, But Can the Rally Continue?2 "Cheap for a Reason" Airline Stocks That May Be Worth the RiskMarketBeat's Most Downgraded Stocks in Q3: 2 Look Cheap, 1 Looks RiskyCould Dave & Buster’s Capitulation Signal the Bottom Is Finally In?Navan's Strong Quarter Meets an AI Spending Reality Check3 Defense Stocks Riding the High-Energy Laser BoomLightPath’s Defense Pivot Could Send Shares Higher Upcoming Earnings Cintas (9/23/2026)Costco Wholesale (9/24/2026)Micron Technology (9/30/2026)NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026)Delta Air Lines (10/8/2026)America Movil (10/13/2026)BlackRock (10/13/2026)Citigroup (10/13/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
